Robert J. Motzer, MD

Articles

Future Perspectives in the Treatment of Advanced RCC

November 3rd 2023

Oncologists discuss the need for more data on treatment duration in advanced RCC, emphasize the value of long-term patient follow-ups, and highlight the translational focus of the KCRS annual meeting, which combines clinical and early-stage research for renal cell carcinoma.

Key Takeaways in the Treatment of Advanced RCC From KCRS 2023

October 27th 2023

Robert Motzer, MD, and Elizabeth Plimack, MD, discuss clinical findings in the treatment of advanced RCC from the recent KCRS 2023 meeting, emphasizing the significance of circulating tumor cells, advances in imaging, and the potential of adjuvant therapies, particularly pembrolizumab.

Managing Long-Term Toxicities of Combination Lenvatinib and Pembrolizumab in Advanced RCC

October 27th 2023

Drs Elizabeth Plimack and Robert Motzer discuss the long-term toxicities of combination lenvatinib/pembrolizumab in patients with advanced RCC, highlighting fatigue, GI discomfort, hand-foot syndrome, liver toxicity, thyroid toxicity, and proteinuria.

Dosing Considerations for Combination Lenvatinib and Pembrolizumab in Patients with Advanced RCC

October 20th 2023

Experts detail their approaches to dosing combination lenvatinib and pembrolizumab for patients with advanced RCC, emphasizing individualized treatment for balanced efficacy and toxicity.

Lenvatinib Plus Pembrolizumab for Firstline Treatment of Advanced RCC

October 20th 2023

Elizabeth Plimack, MD, and Robert Motzer, MD, explain their preferences between TKI-IO combination therapies for patients with advanced RCC considering efficacy, side effects, and specific patient factors.

Available Treatment Options for Patients with Advanced RCC

October 13th 2023

Medical oncologists discuss a patient's surprising rapid decline after an initial diagnosis of clear cell RCC, emphasizing the efficacy of combination lenvatinib/pembrolizumab in similar patients.

Patient Profile Presentation: A 65-Year-Old Man with Advanced Clear Cell Renal Cell Carcinoma (RCC)

October 13th 2023

Robert Motzer, MD, presents the patient profile of a 65-year-old man diagnosed with clear cell RCC for discussion.

Renal Cell Carcinoma: Future Directions in Care

April 22nd 2022

Looking toward the future management of renal cell carcinoma, experts consider treatment strategies for bone metastasis, brain metastasis, and VHL disease.

Non–Clear Cell RCC: Clinical Rationale Behind Therapy

April 22nd 2022

A brief review of the clinical rationale behind therapeutic regimens used for patients with non-clear cell carcinoma.

Patient Profile 4: Non–Clear Cell RCC Treated With Cabozantinib-Nivolumab

April 15th 2022

Experts review a clinical scenario of non–clear cell renal cell carcinoma, wherein the patient is managed with cabozantinib-nivolumab.

Clear Cell RCC: Testing Recommendations and Familial Risk

April 15th 2022

A brief discussion on the genetic risk tied to clear cell renal cell carcinoma and how that may inform familial risk and testing.

Adjuvant and Neoadjuvant Therapies Under Evaluation for Renal Cell Carcinoma

April 8th 2022

Expert perspectives on the possible roles of neoadjuvant nivolumab and adjuvant sunitinib for patients with renal cell carcinoma.

Patient Profile 3: RCC Treated With Adjuvant Pembrolizumab

April 8th 2022

A clinical scenario of renal cell carcinoma treated with surgery and adjuvant pembrolizumab is reviewed by a panel of experts.

Lenvatinib/Pembrolizumab in RCC: Dosing and Adverse Event Management

April 1st 2022

Expert perspectives on lenvatinib/pembrolizumab combination therapy in renal cell carcinoma, including appropriate dosing and adverse event management.

Risk Stratification and Factors in Selecting Therapy in RCC

April 1st 2022

Shared insight on the patient and disease factors that inform the selection of therapy for favorable-risk renal cell carcinoma.

Patient Profile 2: Favorable-Risk RCC Treated With Lenvatinib-Pembrolizumab

March 25th 2022

A second clinical scenario focusing on favorable-risk renal cell carcinoma managed with lenvatinib-pembrolizumab therapy.

Triplet Therapy Approaches for Intermediate/Poor Risk RCC

March 25th 2022

A brief discussion on triplet therapy being investigated in patients with intermediate- and poor-risk renal cell carcinoma.

I/O–I/O Therapy in Intermediate/Poor Risk RCC: Toxicity and Duration of Response

March 18th 2022

Focusing on immunotherapy in the setting of intermediate- and poor-risk renal cell carcinoma, panelists review toxicity management and duration of response.

Patient Profile 1: Intermediate/Poor Risk RCC Treated With Ipilimumab-Nivolumab

March 18th 2022

Experts review a clinical scenario of intermediate- and poor-risk renal cell carcinoma that is managed with ipilimumab-nivolumab and nivolumab maintenance.

Dr. Motzer on the Efficacy of Cabozantinib in RCC

March 18th 2021

Robert J. Motzer, MD, discusses the efficacy of cabozantinib in patients with renal cell carcinoma.